| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| S1507 | A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies | Cancer | Lung |
| S1609 - DART | DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors. Single arm nivolumab and ipilimumab treating patients with rare tumors | Cancer | Rare Tumor |
| TAPUR Study for Advanced Cancers | The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. For more information please visit http://www.tapur.org/patients | Cancer | Genomic testing based trial |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.